Alternatives to Tirzepatide
Alternatives to tirzepatide include semaglutide, liraglutide, and emerging triple agonists. Switching protocols, cost comparisons, and non-medication options.
Semaglutide avg. loss
~15%
Retatrutide (Phase 3)
~24% (Phase 2)
Bariatric surgery
25-35% sustained
Oral options
Orforglipron (Phase 3)
Non-GLP-1 meds
5-9% avg. loss
Semaglutide (Wegovy / Ozempic)
Semaglutide is the most common alternative to tirzepatide. While it produces less weight loss on average (~15% vs. ~22.5%), it has more extensive long-term safety data, proven cardiovascular benefits (SELECT trial), and an oral formulation (Rybelsus). Some patients may also find better insurance coverage for semaglutide.
Semaglutide is available in compounded form at lower cost, and supply has generally been more stable. For patients who experience intolerable side effects with tirzepatide, semaglutide provides a single-agonist option that some tolerate better.
Liraglutide and Older GLP-1 Options
Liraglutide (Saxenda) offers daily dosing with more gradual effects and lower weight loss (~8%). It may be appropriate for patients who prefer a more conservative approach. Dulaglutide (Trulicity) and exenatide (Byetta/Bydureon) are primarily diabetes medications with modest weight loss benefits.
These older options cost less and have the longest safety track records but are being rapidly displaced by semaglutide and tirzepatide for weight management. They remain relevant for diabetes patients who need GLP-1 therapy but have access barriers to newer medications.
Emerging Pipeline Medications
Several next-generation obesity medications are in late-stage development. Retatrutide (Eli Lilly) is a triple agonist targeting GLP-1, GIP, and glucagon receptors, with Phase 2 data showing up to 24% weight loss. Survodutide (Boehringer Ingelheim) is a dual GLP-1/glucagon agonist showing promising results for both obesity and MASH. Orforglipron (Eli Lilly) is an oral GLP-1 that would eliminate the need for injections.
These medications are expected to reach the market in 2026-2028 and may offer additional options for patients who don't respond optimally to current treatments.
Non-GLP-1 Medication Options
For patients who cannot tolerate or access GLP-1/GIP medications, other FDA-approved weight loss drugs include phentermine-topiramate (Qsymia), which produces ~7-9% weight loss; naltrexone-bupropion (Contrave), producing ~5-6% loss; and orlistat (Alli/Xenical), producing ~3-4% loss. These are less effective but more affordable and widely available.
Bariatric surgery remains the most effective single intervention for severe obesity, producing 25-35% sustained weight loss. For qualifying patients (typically BMI >= 40 or >= 35 with comorbidities), surgery may offer outcomes comparable to or exceeding medication.
Frequently Asked Questions
What is the best alternative to tirzepatide?
Semaglutide (Wegovy) is the most comparable alternative, producing ~15% weight loss with extensive safety data and proven cardiovascular benefits. Choice depends on your specific health profile, insurance, and tolerance.
Can I switch from tirzepatide to semaglutide?
Yes, switching between GLP-1 medications is common. Your provider will determine timing and starting dose. Expect to start semaglutide at a low dose and titrate up, even if you were on a high tirzepatide dose.
What comes after tirzepatide if it doesn't work?
Options include adding a non-GLP-1 medication, switching to semaglutide (different receptor profile), considering bariatric surgery for qualifying patients, or waiting for next-generation medications like retatrutide.
Compare all medication options with verified providers
Compare pricing, reviews, and availability across 18,000+ GLP-1 providers nationwide.
Search Providers →Explore all Tirzepatide topics
Cost guides, side effect management, dosing information, insurance coverage, and more — all backed by clinical data.